Astrazeneca (AZN) Current Assets (2009 - 2026)
Astrazeneca (AZN) posted quarterly Current Assets of $28.0 billion for Q2 2026, down 3.37% year-over-year from $28.9 billion in Q2 2025, and down 5.57% quarter-over-quarter from $29.6 billion in Q1 2026.
Astrazeneca (AZN) Current Assets (2009 - 2026) Analysis & Trends
Astrazeneca's Current Assets history runs 18 years deep, the most recent figure standing at $28.0 billion for Q2 2026.
- In Q2 2026, Current Assets fell 3.37% year-over-year to $28.0 billion; the TTM figure through Jun 2026 stood at $28.0 billion (down 3.37% YoY), while the FY2025 annual figure was $28.7 billion, up 11.21% from the prior year.
- Current Assets for Q2 2026 stood at $28.0 billion, down from $29.6 billion in the prior quarter.
- The five-year high for Current Assets was $29.9 billion in Q3 2025, with the low at $20.2 billion in Q3 2022.
- The 5-year median for Current Assets is $25.2 billion (2023), against an average of $25.1 billion.
- Peak annual rise in Current Assets reached 52.99% in 2022, while the deepest fall reached 24.23% in 2022.
- Astrazeneca's Current Assets stood at $22.6 billion in 2022, then climbed by 10.89% to $25.1 billion in 2023, then climbed by 3.09% to $25.8 billion in 2024, then climbed by 11.21% to $28.7 billion in 2025, then decreased by 2.64% to $28.0 billion in 2026.
- Business Quant data shows AZN's Current Assets at $28.0 billion in Q2 2026, $29.6 billion in Q1 2026, and $28.7 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 59.77 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 33.67 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 36.68 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 27.35 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 27.97 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 34.96 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 13.95 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 41.36 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 23.56 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 36.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.97 Bn |
| Mar 31, 2026 | 29.61 Bn |
| Dec 31, 2025 | 28.72 Bn |
| Sep 30, 2025 | 29.94 Bn |
| Jun 30, 2025 | 28.94 Bn |
| Mar 31, 2025 | 26.14 Bn |
| Dec 31, 2024 | 25.83 Bn |
| Sep 30, 2024 | 24.16 Bn |
| Jun 30, 2024 | 25.39 Bn |
| Mar 31, 2024 | 25.59 Bn |
| Dec 31, 2023 | 25.05 Bn |
| Sep 30, 2023 | 22.50 Bn |
| Jun 30, 2023 | 22.84 Bn |
| Mar 31, 2023 | 22.27 Bn |
| Dec 31, 2022 | 22.59 Bn |
| Sep 30, 2022 | 20.22 Bn |
| Jun 30, 2022 | 20.92 Bn |
| Mar 31, 2022 | 22.65 Bn |
| Dec 31, 2021 | 26.24 Bn |
| Sep 30, 2021 | 26.69 Bn |